An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CG Oncology, Inc. (NASDAQ: CGON) will host a virtual investor event on May 3, 2024, to discuss the results from the Phase 3 BOND-003 trial presented at the 2024 AUA Annual Meeting. The company focuses on developing bladder-sparing therapeutics for bladder cancer patients. The event will feature updates on the progress of its oncolytic immunotherapy cretostimogene. Details of the AUA presentation and webcast replay can be found on the company's investor relations website.
CG Oncology, Inc. (NASDAQ: CGON) ospiterà un evento virtuale per investitori il 3 maggio 2024 per discutere i risultati del trial di Fase 3 BOND-003 presentati durante l'incontro annuale dell'AUA del 2024. La società si concentra sullo sviluppo di terapie conservative per la vescica nei pazienti affetti da cancro alla vescica. L'evento includerà aggiornamenti sui progressi della sua immunoterapia oncolitica cretostimogene. I dettagli della presentazione AUA e della replica del webcast sono disponibili sul sito web delle relazioni con gli investitori della compagnia.
CG Oncology, Inc. (NASDAQ: CGON) organizará un evento virtual para inversores el 3 de mayo de 2024 para discutir los resultados del ensayo de Fase 3 BOND-003 presentados en la Reunión Anual de la AUA de 2024. La empresa se centra en el desarrollo de terapias conservadoras de la vejiga para pacientes con cáncer de vejiga. El evento presentará actualizaciones sobre el progreso de su inmunoterapia oncolítica cretostimógeno. Los detalles de la presentación de la AUA y la repetición de la transmisión web están disponibles en el sitio web de relaciones con inversores de la empresa.
CG Oncology, Inc. (NASDAQ: CGON)는 2024년 5월 3일에 가상 투자자 이벤트를 개최하여 2024년 AUA 연례 회의에서 발표된 3상 BOND-003 시험 결과에 대해 논의할 예정입니다. 이 회사는 방광암 환자를 위한 방광 보존 치료법 개발에 중점을 두고 있습니다. 이 행사는 자사의 종양용 아이 미노 테라피 크레토스티모제네의 진행 상황 업데이트를 제공할 것입니다. AUA 발표 세부 사항 및 웹캐스트 재생은 회사의 투자자 관계 웹사이트에서 확인할 수 있습니다.
CG Oncology, Inc. (NASDAQ: CGON) organisera un événement virtuel pour les investisseurs le 3 mai 2024 pour discuter des résultats de l'essai de phase 3 BOND-003 présentés lors de la réunion annuelle de l'AUA de 2024. L'entreprise se concentre sur le développement de thérapies préservant la vessie pour les patients atteints de cancer de la vessie. L'événement présentera des mises à jour sur les progrès de son immunothérapie oncolytique cretostimogène. Les détails de la présentation de l'AUA et la rediffusion du webcast peuvent être trouvés sur le site web des relations investisseurs de l'entreprise.
CG Oncology, Inc. (NASDAQ: CGON) wird am 3. Mai 2024 ein virtuelles Investorentreffen veranstalten, um die Ergebnisse der Phase-3-Studie BOND-003 zu diskutieren, die auf dem Jahresmeeting der AUA 2024 vorgestellt wurden. Das Unternehmen konzentriert sich auf die Entwicklung von blaserhaltenden Therapien für Blasenkrebspatienten. Bei der Veranstaltung werden Updates über den Fortschritt ihrer onkolytischen Immuntherapie Cretostimogene präsentiert. Details zur AUA-Präsentation und zur Wiedergabe des Webcasts finden sich auf der Investor Relations-Website des Unternehmens.
Positive
None.
Negative
None.
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting
IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT. The executive leadership team will provide updates on the company’s progress, following an oral presentation of its oncolytic immunotherapy cretostimogene at the American Urological Association (AUA) Annual Meeting in San Antonio, TX.
CG Oncology will broadcast the presentations live on the company's investor relations website, https://ir.cgoncology.com, where a webcast replay will also be available following the event.
Details of the AUA oral presentation are as follows:
Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ Abstract Number: 24-11358 Session: Paradigm-shifting, Practice-changing Clinical Trials in Urology Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ Presentation Date & Time: May 3, 2024, 10:23-10:31am CDT Location: Henry B. González Convention Center, Stars at Night Ballroom
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene was previously evaluated in a Phase 2 clinical trial (CORE-001) in combination with pembrolizumab in the same indication and is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in intermediate-risk NMIBC patients. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Investor Relations Laurence Watts New Street IR (619) 916-7620 IR@cgoncology.com
When will CG Oncology host a virtual investor event?
CG Oncology will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.
What is the focus of CG Oncology's development?
CG Oncology focuses on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer.
What will be discussed during the virtual investor event?
The executive leadership team will provide updates on the company’s progress, following an oral presentation of its oncolytic immunotherapy cretostimogene at the American Urological Association (AUA) Annual Meeting in San Antonio, TX.
Where can the presentations be viewed live?
CG Oncology will broadcast the presentations live on the company's investor relations website at https://ir.cgoncology.com.
Who will be presenting at the AUA Annual Meeting?
Dr. Mark D. Tyson, a Urologic Oncologist at Mayo Clinic, Scottsdale, AZ, will be presenting the Phase 3 results from the BOND-003 trial.
